Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma

We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10–21) weeks. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zekri, J M, Hough, R E, Davies, J M, Molife, R, Hancock, B W, Lorigan, P C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741047/
https://www.ncbi.nlm.nih.gov/pubmed/12778057
http://dx.doi.org/10.1038/sj.bjc.6600914
Descripción
Sumario:We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10–21) weeks. The median overall survival was 70 (9–178) weeks and for responders it was 120 (22–178) weeks. One patient developed one episode of neutropenic sepsis. Docetaxel has limited activity in this group of patients.

Ejemplares similares